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PANDER is a cytokine co-secreted with insulin from islet b-cells. To date, the physiological function
of PANDER remains largely unknown. Here we show that PANDER binds to the liver membrane by
125I-PANDER saturation and competitive binding assays. In HepG2 cells, pre-treatment with PANDER
ranging from 4 pM to 4 nM for 8 h resulted in a maximal inhibition of insulin-stimulated activation
of insulin receptor and insulin receptor substrate 1 by 52% and 63%, respectively. Moreover, PANDER
treatment also reduced insulin-stimulated PI3K and pAkt levels by 55% and 48%, respectively. In
summary, we have identiﬁed the liver as a novel target for PANDER, and PANDER may be involved
in the progression of diabetes by regulating hepatic insulin signaling pathways.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
It was estimated that the number of people with diabetes,
mainly type 2 diabetes, had reached 171 million in 2000 and it
would reach 366 million by 2030 worldwide. Diabetes is becom-
ing one of the major diseases threatening our health worldwide
[1]. Although the pathogenesis of type 2 diabetes is still poorly
understood, it is now widely accepted that insulin resistance in
the peripheral tissues plays a major role in its development [2].
The liver is one of the major insulin target tissues and plays a
crucial role in glucose homeostasis by converting glucose to gly-
cogen after meals and producing glucose from gluconeogenesis
and glycogenolysis in fasting [3,4]. The binding of insulin to its
receptor on the liver membrane activates its intrinsic tyrosine ki-
nase activity, which results in recruitment and tyrosine phos-
phorylation of multiple insulin receptor substrates (IRSs),
among which IRS-1 and IRS-2 play a vital role. Tyrosine phos-
phorylated IRS-1 and IRS-2 bind to PI3K, triggering downstream
signaling cascade to regulate glucose homeostasis [3]. It has been
established that exposure to high levels of proinﬂammatory cyto-chemical Societies. Published by E
ad, Beijing 100191, PR China
lvd., Philadelphia, PA 19104-
fb@mail.med.upenn.edu (B.A.kine including interleukin 6 (IL-6) and tumor necrosis factor-
a(TNF-a) would inhibit insulin signaling pathways in liver cells
[5,6]. Recently, increasing evidence has indicated that adipose-
derived resistin, adiponectin, visfatin, omentin and other adipo-
kines plays an important role in obesity-related type 2 diabetes
and insulin resistance [7–10]. In the past decade, extensive stud-
ies of newly-discovered cytokines including resistin, visfatin and
omentin had shed new light on understanding and treatment of
type 2 diabetes.
PANcreatic DERived factor (PANDER, FAM3B) is a cytokine
cloned in 2002 with highly speciﬁc expression in pancreatic islets
[11]. Our previous studies have demonstrated that recombinant
PANDER treatment or adenoviral overexpression will induce apop-
tosis of a- and b-cells of mouse, rat, and human islets [12,13]. Fur-
ther studies revealed that glucose potently up-regulated the
PANDER promoter activity in pancreatic islets and stimulated PAN-
DER secretion from pancreatic islet b-cells through the same secre-
tory granules with insulin [14–17], implying a potential role of
PANDER in glucose homeostasis. More recently, we demonstrated
that the PANDER promoter activity was also regulated by PDX-1
[16], further conﬁrming that the expression of PANDER was regu-
lated in a manner similar to insulin. Until now, the PANDER recep-
tor has not been identiﬁed and the physiological function of
PANDER still remains unknown. Therefore, the goal of this study
was to investigate the biological role of PANDER by identifying
its potential target tissues. We have identiﬁed the liver as a novellsevier B.V. All rights reserved.
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insulin signaling pathways in vitro.2. Materials and methods
2.1. Preparation of tissue membranes
Various tissues were dissected from 6 to 8 mice, and frozen
immediately on dry ice and kept frozen at 80 C for 2 weeks to
2 months until processed for membrane preparation and binding
studies. For extraction of the membrane, 0.5–1 g of tissue was
thawed on ice, and then homogenized in 10 volume of 0.32 M su-
crose for 1 min on ice. The homogenate was centrifuged at 1000g
at 4 C for 10 min, and the supernatant was carefully subjected to
centrifuge at 30 000g for 30 min at 4 C. The resulting pellet was
resuspended in ice-cold sample buffer (50 mM Tris–HCl, 2 mM
EGTA, 0.03% bacitracin, pH 7.3) and immediately used for protein
content determination by bicinchoninic acid assay and for binding
assay [18–20]. HepG2 cell membranes was also prepared as above.
2.2. Iodination of PANDER
Four iodobeads and 2 mCi of 125I were preincubated for 5 min.
Recombinant mouse PANDER (50 lg) was added to the activated
beads, and incubated 15 min with occasional stirring. The 125I-
PANDER was incubated 5 min with pre-washed Dowex beads,
and the supernatant neutralized with NaOH to pH 7.2. The speciﬁc
activity of 125I-PANDER was 40 lCi/lg PANDER.
2.3. Saturation binding assay
Tissue membranes (corresponding to 400 lg protein) were
incubated with increasing concentrations of 125I labeled-mouse-
PANDER (0.1 nM to 10 nM, speciﬁc activity: 40 lCi/lg PANDER) in
the absence and presence of 2 lM cold mouse PANDER in a ﬁnal
volume of 500 ll binding buffer (50 mM Tris–HCl, 2 mM EGTA,
0.03% bacitracin, 0.1% BSA, pH 7.3) at room temperature for 2 h.
Each condition was assayed in triplicate. The binding reaction
was terminated by a rapid ﬁltration through a Whatman GF/B ﬁl-
ter, which was presoaked with 2 mL of 0.5% polyethyleneimine
for prevention of excessive binding of free radioactive ligand to
the ﬁlter, by a MILLIPORE 1225 Sampling Manifold. The ﬁlter was
rinsed three times with 2 mL of ice-cold binding buffer, and then
was punched into a 12  75 mm glass tube. The radioactivity re-
tained in the ﬁlter was measured by a gamma counter. Speciﬁc
binding activity was obtained by subtracting the unspeciﬁc bind-
ing at presence of 200-fold cold PANDER from the total binding
[18–20].
2.4. Cross-linking experiments
The experiment was performed according to the manufacturer’s
instructions (Sulfo-SBED biotin label transfer kit, Pierce). Brieﬂy,
recombinant mouse PANDER was diluted to 0.4 lg/ll in PBS solu-
tion. Sulfo-SBED was dissolved in 100 ll DMF to a ﬁnal concentra-
tion of 10 lg/ll. Two microliters Sulfo-SBED was added into 300 ll
diluted PANDER protein solution, and the mixture was incubated
at room temperature (RT) for 30 min in darkness. Then, the
SEBD-PANDER complex was dialyzed in darkness at 4 C overnight
against 500 mL dialysis buffer containing 0.005% Tween-20. Dialy-
sis buffer was changed once during dialysis. The labeled PANDER
and the liver cell membrane were incubated at ratio of 1:20 at
RT for 1 h in darkness. After incubation, each sample was exposed
to UV light (312 nm wavelength) for 6 min (sample under the light
at 5 cm; Wattage: 15  6W light bulbs). After UV light exposure,the sample was boiled in 5  SDS loading buffer with 500 mM
DTT at 95 C for 5 min. The treated sample was subjected to Wes-
tern blot using HRP-conjugated streptavidin antibody.
2.5. Competitive binding assay
The membrane (correspond to 400 lg protein) was incubated
with 2.5 nM 125I-PANDER (mouse) plus increasing concentrations
of cold mouse PANDER (0 nM to 1 lM) in a ﬁnal volume of
500 ll binding buffer at room temperature for 2 h. The radioactiv-
ity retained in the ﬁlter was determined as described above. The
parallel incubations, where 2.5 lM of cold PANDER was also pres-
ent, were used as non-speciﬁc binding and subtracted from total
binding to yield speciﬁc binding values.
2.6. Antibodies
IRb, IRS-1, pIRS-1(Tyr989), PI3K(p85a), Akt, pAkt(Ser473) and
pAkt(Thr308) antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Anti Phosphotyrosine antibody (4G10)
was purchased from Upstate Biotechnology (Charlottesville, VA).
HRP-conjugated secondary antibody was purchased from Jackson
Immunoresearch (West Grove, PA).
2.7. Cell culture
Human hepatocarcinoma cell line (HepG2) was purchased from
American Type Culture Collection (Rockville, MD). HepG2 cells
within 8th passage were cultured at 37 C in 5% CO2–95% air in
DMEM medium supplemented with 10% FBS, 2 mM glutamine,
100 lg/mL streptomycin and 100 IU/mL penicillin. The cells were
split weekly and the medium changed twice in a week.
2.8. PANDER treatment of HepG2 cells
HepG2 cells were seeded in 6-cm dish with normal DMEMmed-
ium. Cells were washed once with serum-free DMEM medium
containing 1% BSA when they were 60–80 conﬂuent, and then ser-
um-starved for 16–18 h [21]. After serum-starvation, the cells were
treated with recombinant mouse PANDER for various time lengths,
followed by stimulation with 100 nM insulin (NOVO) for 5 min at
37 C. The cells were quickly washed twice with ice-cold PBS,
and then lysed in fresh Roth Lysis (50 mM HEPES, 150 mM NaCl,
1% Triton X-100, 5 mM EDTA, 5 mM EGTA, 20 mM Na Pyrophos-
phate, 20 mM NaF, 0.2 mg/mL PMSF, 0.01 mg/mL leupeptin,
0.01 mg/mL aprotinin and 1% Phosphatase Inhibitor Cocktail II,
pH 7.4) by scraping and pipetting on ice. The lysate were centri-
fuged at 13 000 rpm at 4 C for 10 min, and the protein content
in the supernatant was determined by bicinchoninic acid assay.
Five hundred micrograms total proteins were subjected to immu-
noprecipitation immediately.
2.9. MTT assay of cell viability
HepG2 cells were seeded in 24-well plates and treated with var-
ious concentrations of PANDER for 48 h. The cells were washed
twice with 1 mL of prewarmed KRB. Cells were then incubated at
37 C in 5% CO2 for 1 h in 1 mL of KRB containing 20 mM glucose
and 0.5 mg/mL MTT (C,N-diphenyl-4,5-dimethyl thiazol-2-yl tetra-
zolium bromide). The supernatant was aspirated, and 0.5 mL/well
2-propanol was added. The plate was incubated at room tempera-
ture in darkness for 1 h to completely dissolve formazan crystals.
The absorbance was measured at 560 nm using Wallac 1420 Mul-
tilabel Counter (PerkinElmer Life Sciences, Gaithersburg, MD) [12].
As a positive control of cell apoptosis, 1 h before MTT assays, some
cells were treated with 1 lM of H2O2.
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The immunoprecipitation was performed as described previ-
ously [22,23]. In brief, 500 lg (HepG2 cells) total protein were
pre-cleared with 20 ll protein A sepharose CL-4B bead in a ﬁnal
volume of 750 ll at 4 C for 1 h, and then the sample was spinned
at 13 000 rpm at 4 C for 1 min. Pellet disposed. Ten microliters pri-
mary antibody (200 lg/mL) was added into the supernatant, rotat-
ing on a Nutator for 2 h at 4 C. After 2 h, 50 ll CL-4B bead was
added into each tube, rotating on Nutator at 4 C overnight. The
sample was spin at 13 000 rpm for 1 min, and the resulting pellet
bead was washed twice with 0.5 mL buffer I (1% Triton X-100,
0.1% SDS, 50 mM HEPES and 150 mM NaCl, pH 7.8) and buffer II
(1% Triton X-100, 0.1% SDS and 50 mM HEPES, pH 7.8), respec-
tively. The ﬁnal pellet was suspended in 50 ll 2  SDS loading buf-
fer containing 50 mM DTT, and boiled for 6 min in a water bath.
The boiled sample was centrifuged at 13 000 rpm at room temper-
ature for 4 min, and 20 ll supernatant was separated by 4–20% SDS
gradient gel (Pierce). Immunoblot assay was performed as de-
scribed previously. Finally, the membrane was developed with
ECL. After immunoblot assay of the phosphorylated protein, the
membrane was stripped with 0.2 N NaOH and re-probed using
1:500 dilution corresponding non-phosphorylated protein anti-
body. For detection of pAkt, 50 lg total proteins were subjected
to immunoblot assay as above.
2.11. Quantiﬁcation of target protein
The amount of protein was determined using software Multi
Gauge (version 3.0, FUJIFILM). All data were normalized to the con-
trol value. The result of each experiment represented the average
of three independent scans and calculations. The data were ob-
tained from at least ﬁve independent experiments.Fig. 1. Saturation and competitive binding of 125I-PANDER to liver membrane. (A) Saturat
125I-PANDER in the absence or presence of excessive cold PANDER at room temperatu
described in Section 2. (B) Competitive binding assay. Liver membrane was incubated wit
temperature, and then radioactivity bound to the membrane was determined as above. (C
liver cell membrane. (D) 125I-PANDER binded to HepG2 cell membrane. The data we
experiments using different mice liver membrane.2.12. Statistical analysis
Data are presented as mean ± S.E.M. Statistical signiﬁcance of
differences between groups was analyzed by paired Student’s t-
test or by one-way analysis of variance (ANOVA) when more than
two groups were compared.3. Results
3.1. PANDER binded to the liver membrane
Our prior results have shown that PANDER is co-secreted from
the b-cell with insulin through a similar regulatory mechanisms
following glucose challenge [15]. This observation strongly sug-
gested that PANDER might act on other tissues besides islets by
functioning as an endocrine factor. To address this hypothesis,
we screened mouse tissue membranes using an in vitro 125I-PAN-
DER binding assay to identify the potential target tissues of PAN-
DER. The saturation binding results indicated that 125I-PANDER
dose-dependently binds to liver membranes with a 150 fmol/
mg protein at the concentration of 10 nM (Fig. 1A). In contrast,
no 125I-PANDER binding had been detected in brain, pancreatic,
adipose or kidney membranes (data not shown). To further conﬁrm
the speciﬁcity of binding of 125I-PANDER to liver membranes, a
competitive binding assay was performed. The results indicated
clearly that binding of 125I-PANDER to liver membrane was com-
petitively inhibited by increasing concentrations of cold PANDER,
with an EC50 of about 16 nM (Fig. 1B). These results strongly sug-
gest that PANDER binds to liver membranes. Cross-linking experi-
ment further conﬁrmed that PANDER interacted with some
unknown protein on the liver cell membrane (Fig. 1C). Unexpect-
edly, 125I-PANDER did not bind to pancreatic membrane.ion binding assay. Liver membrane was incubated with increasing concentrations of
re for 2 h, and radioactivity binding bound to the membrane was determined as
h 2.5 nM 125I-PANDER plus increasing concentrations of cold PANDER for 2 h at room
) Cross-linking assay indicated that PANDER binded with an unknown protein in the
re collected from 5 (saturation binding) or 3 (competitive binding) independent
Fig. 2. Effect of PANDER treatment on insulin-stimulated tyrosine phosphorylation
of insulin receptor in a HepG2 cell line. HepG2 cells were serum-starved and treated
with 4 nM PANDER for various lengths of time, followed by stimulation with
100 nM insulin for 5 min. This membrane was also re-probed with insulin receptor
(IR) antibody for total IR as a loading control (A). The data shown in (B) were
collected from at least ﬁve independent experiments. *P < 0.05, **P < 0.01 when
compared to non-treated.
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Because the 125I-PANDER binding experiments had suggested
that the liver may be one potential target tissue for PANDER
(Fig. 1A and C), we then evaluated whether PANDER impactedFig. 3. Effect of PANDER treatment on insulin-stimulated tyrosine phosphorylation of in
concentrations for 8 h (A) or with 4 nM PANDER for various lengths of time (B), and then i
Western blot (C and D). This data was then normalized to a non-treated control sample (
**P < 0.01 when compared to non-treated.insulin signaling in HepG2 cells. Firstly, we conﬁrmed that 125I-
PANDER also binds to the membrane of HepG2 cells (Fig. 1D).
We then evaluated the impact of 4 nM PANDER pre-treatment
for 8 h on insulin-stimulated tyrosine phosphorylation of insulin
receptor (IR). The concentration 4 nM was chosen because our
previous study indicated that it is an effective dose to induce
pancreatic b-cell death [13]. The insulin-stimulated IR tyrosine
phosphorylation after 5-min, 2 h, 4 h and 8 h of PANDER treat-
ment was 97 ± 8%, 83 ± 7%, 63 ± 7% (P < 0.05) and 48 ± 4%
(P < 0.01) of the control without PANDER treatment, respectively
(Fig. 2). The results indicated that PANDER inhibited IR tyrosine
phosphorylation in a time-dependent manner. PANDER treat-
ment had no effect on tyrosine phosphorylation in the absence
of insulin stimulation and IR content (Fig. 2). Since PANDER
inhibited tyrosine phosphorylation of IR, we then evaluated the
dose and time- dependent impact of PANDER on insulin-stimu-
lated tyrosine phosphorylation of insulin substrate 1 (IRS-1).
The dose-curve indicated that the minimal PANDER concentra-
tion for signiﬁcantly inhibiting insulin-stimulated IRS-1 tyrosine
phosphorylation within 8 h was 400 pM, which inhibited phos-
phorylation by about 36%, while 4 nM inhibited about 54%. Four
pM (99 ± 5%) and forty pM (97 ± 12%) had no signiﬁcant effect on
tyrosine phosphorylation of IRS-1 (Fig. 3). In a time-course assay,
the cells were treated with 4 nM PANDER for various lengths of
time. The tyrosine phosphorylation of insulin-stimulated IRS-1
after 2 h, 4 h and 8 h with 4 nM PANDER treatment was 65 ± 4%
(P < 0.05), 58 ± 5% (P < 0.05) and 37 ± 5% (P < 0.01), respectively.
As expected, a 5-min treatment had no effect on IRS-1 tyrosine
phosphorylation (Fig. 3). In all experiments, PANDER treatment
had no signiﬁcant effect on IRS-1 tyrosine phosphorylation and
IRS-1 content without insulin stimulation, which indicated that
PANDER treatment does not increase the degradation of the
IRS-1 protein.sulin receptor in a HepG2 cell line. HepG2 cells were treated with various PANDER
nsulin-stimulated IRS-1 tyrosine phosphorylation was evaluated and quantitated by
C, D). The data were collected from at least ﬁve independent experiments. *P < 0.05,
Fig. 5. Effects of long-term PANDER pre-treatment on cell viability of HepG2 cells.
HepG2 cells were treated with various concentration of PANDER for 48 h. The
viability of treated HepG2 cells was evaluated by MTT assays. **P < 0.01 when
compared to other groups.
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in HepG2 cells, the effect of PANDER on insulin-stimulated PI3K
and phosphorylation of Akt was assayed. Insulin-stimulated PI3K
levels after treatment with 4 nM PANDER for 2 h, 4 h and 8 h were
76 ± 8% (P < 0.05), 66 ± 7% (P < 0.05) and 46 ± 3% (P < 0.01), respec-
tively. Not surprisingly, 5 min of treatment had no effect on PI3K
levels (Fig. 4A and B). Basal PI3K without insulin stimulation was
also unchanged by PANDER treatment (Fig. 4A). Insulin-stimulated
Ser473 phosphorylation of Akt was also inhibited by PANDER
treatment, which was 88 ± 13%, 69 ± 11%, 60 ± 10% (P < 0.05) and
52 ± 7% (P < 0.05) after treatment with 4 nM PANDER for 5 min,
2 h, 4 h and 8 h, respectively (Fig. 4A and C). Insulin-stimulated
threonine phosphorylation of Akt at 308 was also similarly inhib-
ited by PANDER treatment (Fig. 4A and C). These studies also indi-
cated that PANDER treatment had no effect on Akt content. In
addition, pre-treatment with increasing concentrations of PANDER
up to 4 nM for 48 h had no effect on cell viability of HepG2 cells
(Fig. 5). In summary, PANDER inhibited insulin signaling in a dose-
and time-dependent manner in the HepG2 cell line.
4. Discussion
To date, the physiological function of PANDER remains largely
unknown. Clearly, to identify the potential target tissues of PANDER
will be vital for elucidating its physiological function. In the previ-
ous studies, we had demonstrated that recombinant PANDER treat-
ment induced b-cell apoptosis of human and rodent islets [13,24].
Islet had therefore been expected to be one potential target tissue
of PANDER. Since it is hard to extract sufﬁcient membrane for bind-
ing assays from isolated islets, the whole pancreatic membrane was
prepared. Unexpectedly, saturation binding results indicated that
125I-PANDER did not bind to pancreatic membrane (data not
shown). One possibility is that the ratio of islet membrane to pan-Fig. 4. Effect of PANDER on PI3K and pAKT levels in a HepG2 cell line. HepG2 cells were tr
insulin for 5 min. Following immunoprecipitation with IRS-1, levels of insulin-stimulated
Quantiﬁcation and normalization of the data to non-treated value for PI3K (B) and pA
experiments. *P < 0.05, **P < 0.01 when compared to non-treated value.creatic membrane is too low to be detected in in vitro binding sys-
tem. However, we cannot rule out the possibility that PANDER
functions as an endocrine factor rather than a local cytokine in islets,
since it had been demonstrated to be secreted [15]. In support,
transgenic mouse with islet-speciﬁc overexpression of PANDER
did not show reduced isletmasswhen compared towild typemouse
(Cooperman et al., unpublished data). So we further tested whether
PANDER binded to other tissue membranes. Saturation binding as-
says revealed that 125I-PANDER binded to liver membrane with an
afﬁnity of 150 fmol/mg tissue protein at the concentration 10 nM
(Fig. 1A). In contrast, no binding of 125I-PANDER to brain, kidney
and adiposemembranes had been observed (data not shown). Mus-
cle membrane binding experiment was not performed in our study.
Competitive binding assay further conﬁrmed that binding ofeated with 4 nM PANDER for various time lengths, and then stimulated with 100 nM
PI3K, Ser473 and Thr308 phosphorylation of Akt were detected by immunoblot (A).
kt (Ser473) (C) is shown. The data were collected from at least ﬁve independent
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linking experiment further revealed that PANDER interacted with
some unknown protein on the liver cell membrane (Fig. 1C). These
observations strongly suggested that liver is one novel target tissue
of PANDER. Actually, many cytokines had been reported to act on li-
ver and regulate hepatic glucose and lipid metabolism. Adipose-de-
rived adiponectin activates a speciﬁc signaling though its receptors
in the liver cell membrane, resulting in inhibition of gluconeogene-
sis and increase of glucose uptake and fatty acid oxidation in the li-
ver [25,26]. Overexpression of visfatin signiﬁcantly enhanced global
insulin sensitivity and insulin signaling in rat liver [27]. In contrast,
chronic exposure to high levels of resistin, IL-6 and interleukine-
1(IL-1) increased gluconeogenesis via inhibition of hepatic insulin
signaling [21,28]. More recently, Larsen and colleagues demon-
strated that treatment with interleukin-1 receptor antagonist sig-
niﬁcantly improved fasting blood glucose of type 2 diabetic
patients [29].
To further evaluate whether PANDER affect insulin signaling in
the liver cell, human hepatocellular liver carcinoma cell line HepG2
cells were treated with increasing concentrations of recombinant
mouse PANDER for various lengths of time. Insulin-stimulated acti-
vation of some key molecules in insulin signaling pathways were
assayed. The results indicated that the minimal PANDER concen-
tration for signiﬁcantly inhibiting insulin-stimulated IRS-1 tyro-
sine phosphorylation within 8 h was 400 pM (about 8 ng/mL),
which was comparable to the concentration of other proinﬂamma-
tory cytokines tested in previous studies [21,28]. Overall, 4 nM
PANDER treatment for 8 h inhibited insulin-stimulated tyrosine
phosphorylation of IR and IRS-1 and activation of PI3K and Akt
by more than 50% (Figs. 2–4). In support, the insulin signaling
pathways in the liver of transgenic mouse speciﬁcally overexpress-
ing PANDER in islet was signiﬁcantly inhibited (Cooperman et al.,
unpublished data). These observations strongly suggested that li-
ver is a novel target tissue of PANDER.
Amylin, also known as IAPP (islet amyloid polypeptide), is an-
other small peptide co-secreted with insulin from islet b-cells.
High blood glucose activates amylin gene expression and stimu-
lates amylin secretion in pancreatic b-cells with insulin, resulting
in elevated circulating amylin under type 2 diabetic conditions
[30,31]. Recently, amylin was reported to be deposited in the kid-
neys of patients with diabetes, and the deposition of amylin in the
kidney was associated with renal disease severity [32]. At present,
it is hard to effectively analyze the circulating PANDER level due to
deﬁciency of high-sensitive ELISA kit. But since physiological glu-
cose has been shown to activate the PANDER expression and stim-
ulate its secretion in islet b-cells in previous studies published by
us and others [14–17], it is reasonable to speculate that circulating
PANDER may be increased in insulin-resistant status (prediabetes)
due to increased insulin secretion and islet hypertrophy. Actually,
circulating insulin level was increased by 10–50-folds in db/db or
ob/ob mice. Thus, excessive PANDER may play an important role
in the conversion of prediabetes to diabetes via inhibition of hepa-
tic insulin signaling pathways.
In summary, the current study revealed for the ﬁrst time that
liver is a novel target tissue of PANDER and excessive PANDER
inhibited hepatic insulin signaling pathways. Thus, PANDER might
be involved in the development and progression of type 2 diabetes.
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